Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RLYB - Rallybio Corp


IEX Last Trade
1.155
-0.035   -3.030%

Share volume: 35,129
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.19
-0.04
-2.94%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
1.77%
1 Month
-11.54%
3 Months
-27.67%
6 Months
-48.20%
1 Year
-79.39%
2 Year
-89.63%
Key data
Stock price
$1.16
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.09 - $5.96
52 WEEK CHANGE
-$0.79
MARKET CAP 
47.711 M
YIELD 
N/A
SHARES OUTSTANDING 
41.488 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$61,545
AVERAGE 30 VOLUME 
$80,765
Company detail
CEO:
Region: US
Website: rallybio.com
Employees: 48
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

rallybio is a privately-held early-stage biotechnology company incorporated in january 2018. our ambition is to create a world-leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development. we will work on highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies. rallybio’s founders are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. the company is based in farmington, ct, at the university of connecticut’s technology incubation program. we are assembling a small team of people with an outstanding track record in pharmaceutical research and development to search for and evaluate assets using a series of robust clinical and commercial filters tha

Recent news